Apellis Pharmaceuticals Inc (NAS:APLS)
$ 39.965 0.285 (0.72%) Market Cap: 4.85 Bil Enterprise Value: 4.60 Bil PE Ratio: 0 PB Ratio: 18.17 GF Score: 38/100

Q2 2023 Apellis Pharmaceuticals Inc Earnings Call Transcript

Jul 31, 2023 / 12:30PM GMT
Release Date Price: $25.75 (-19.58%)
Operator

Good day, and thank you for standing by. Welcome to Apellis Pharmaceuticals Second Quarter 2023 Earnings Conference Call. (Operator Instructions) Please be advised that today's conference is being recorded. I would now like to hand the conference over to your speaker today, Meredith Kaya. Please go ahead.

Meredith Kaya
Apellis Pharmaceuticals, Inc. - SVP, IR & Strategic Finance

Good morning, and thank you for joining us today. Earlier this morning, we reported our second quarter 2023 financial results. We will be happy to take questions from you on these results in the Q&A session. However, we will be focusing our prepared remarks today on SYFOVRE, including feedback from the recent ASRS Annual Meeting and an update on our comprehensive review of the rare safety events. With me on the call are Co-Founder and Chief Executive Officer, Dr. Cedric Francois; Chief Commercial Officer, Adam Townsend; Chief Medical Officer, Dr. Caroline Baumal; and Chief Financial Officer, Tim Sullivan.

Before we begin, let me point out that we will be making forward

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot